Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Population Control: Cortical Interneurons Modulate Oligodendrogenesis.

Bandopadhayay P, Stiles CD.

Neuron. 2017 May 3;94(3):415-417. doi: 10.1016/j.neuron.2017.04.032.

2.

A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2.

Zhou J, Tien AC, Alberta JA, Ficarro SB, Griveau A, Sun Y, Deshpande JS, Card JD, Morgan-Smith M, Michowski W, Hashizume R, James CD, Ligon KL, Snider WD, Sicinski P, Marto JA, Rowitch DH, Stiles CD.

Cell Rep. 2017 Mar 28;18(13):3167-3177. doi: 10.1016/j.celrep.2017.03.003.

3.

Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability.

Paolella BR, Gibson WJ, Urbanski LM, Alberta JA, Zack TI, Bandopadhayay P, Nichols CA, Agarwalla PK, Brown MS, Lamothe R, Yu Y, Choi PS, Obeng EA, Heckl D, Wei G, Wang B, Tsherniak A, Vazquez F, Weir BA, Root DE, Cowley GS, Buhrlage SJ, Stiles CD, Ebert BL, Hahn WC, Reed R, Beroukhim R.

Elife. 2017 Feb 8;6. pii: e23268. doi: 10.7554/eLife.23268.

4.

Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.

Ramkissoon SH, Bandopadhayay P, Hwang J, Ramkissoon LA, Greenwald NF, Schumacher SE, O'Rourke R, Pinches N, Ho P, Malkin H, Sinai C, Filbin M, Plant A, Bi WL, Chang MS, Yang E, Wright KD, Manley PE, Ducar M, Alexandrescu S, Lidov H, Delalle I, Goumnerova LC, Church AJ, Janeway KA, Harris MH, MacConaill LE, Folkerth RD, Lindeman NI, Stiles CD, Kieran MW, Ligon AH, Santagata S, Dubuc AM, Chi SN, Beroukhim R, Ligon KL.

Neuro Oncol. 2017 Jul 1;19(7):986-996. doi: 10.1093/neuonc/now294.

5.

A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.

Sun Y, Alberta JA, Pilarz C, Calligaris D, Chadwick EJ, Ramkissoon SH, Ramkissoon LA, Garcia VM, Mazzola E, Goumnerova L, Kane M, Yao Z, Kieran MW, Ligon KL, Hahn WC, Garraway LA, Rosen N, Gray NS, Agar NY, Buhrlage SJ, Segal RA, Stiles CD.

Neuro Oncol. 2017 Jun 1;19(6):774-785. doi: 10.1093/neuonc/now261.

6.

Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.

Selt F, Hohloch J, Hielscher T, Sahm F, Capper D, Korshunov A, Usta D, Brabetz S, Ridinger J, Ecker J, Oehme I, Gronych J, Marquardt V, Pauck D, Bächli H, Stiles CD, von Deimling A, Remke M, Schuhmann MU, Pfister SM, Brummer T, Jones DT, Witt O, Milde T.

Oncotarget. 2017 Feb 14;8(7):11460-11479. doi: 10.18632/oncotarget.14004.

7.

Challenges in Targeting a Basic Helix-Loop-Helix Transcription Factor with Hydrocarbon-Stapled Peptides.

Edwards AL, Meijer DH, Guerra RM, Molenaar RJ, Alberta JA, Bernal F, Bird GH, Stiles CD, Walensky LD.

ACS Chem Biol. 2016 Nov 18;11(11):3146-3153. Epub 2016 Oct 4.

8.

Tyrosine receptor kinase B is a drug target in astrocytomas.

Ni J, Xie S, Ramkissoon SH, Luu V, Sun Y, Bandopadhayay P, Beroukhim R, Roberts TM, Stiles CD, Segal RA, Ligon KL, Hahn WC, Zhao JJ.

Neuro Oncol. 2017 Jan;19(1):22-30. doi: 10.1093/neuonc/now139. Epub 2016 Jul 10.

9.

Gliomas "Dope Up" for Growth.

Paolella BR, Stiles CD.

Cancer Cell. 2016 Jun 13;29(6):778-780. doi: 10.1016/j.ccell.2016.05.010.

10.

MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism.

Bandopadhayay P, Ramkissoon LA, Jain P, Bergthold G, Wala J, Zeid R, Schumacher SE, Urbanski L, O'Rourke R, Gibson WJ, Pelton K, Ramkissoon SH, Han HJ, Zhu Y, Choudhari N, Silva A, Boucher K, Henn RE, Kang YJ, Knoff D, Paolella BR, Gladden-Young A, Varlet P, Pages M, Horowitz PM, Federation A, Malkin H, Tracy AA, Seepo S, Ducar M, Van Hummelen P, Santi M, Buccoliero AM, Scagnet M, Bowers DC, Giannini C, Puget S, Hawkins C, Tabori U, Klekner A, Bognar L, Burger PC, Eberhart C, Rodriguez FJ, Hill DA, Mueller S, Haas-Kogan DA, Phillips JJ, Santagata S, Stiles CD, Bradner JE, Jabado N, Goren A, Grill J, Ligon AH, Goumnerova L, Waanders AJ, Storm PB, Kieran MW, Ligon KL, Beroukhim R, Resnick AC.

Nat Genet. 2016 Mar;48(3):273-82. doi: 10.1038/ng.3500. Epub 2016 Feb 1.

11.

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies.

Chadwick EJ, Yang DP, Filbin MG, Mazzola E, Sun Y, Behar O, Pazyra-Murphy MF, Goumnerova L, Ligon KL, Stiles CD, Segal RA.

J Vis Exp. 2015 Nov 7;(105):e53304. doi: 10.3791/53304.

12.

Of Brains and Blood: Developmental Origins of Glioma Diversity?

Filbin MG, Stiles CD.

Cancer Cell. 2015 Oct 12;28(4):403-404. doi: 10.1016/j.ccell.2015.09.013.

13.

An amino terminal phosphorylation motif regulates intranuclear compartmentalization of Olig2 in neural progenitor cells.

Meijer DH, Sun Y, Liu T, Kane MF, Alberta JA, Adelmant G, Kupp R, Marto JA, Rowitch DH, Nakatani Y, Stiles CD, Mehta S.

J Neurosci. 2014 Jun 18;34(25):8507-18. doi: 10.1523/JNEUROSCI.0309-14.2014.

14.

Olig1 function is required to repress dlx1/2 and interneuron production in Mammalian brain.

Silbereis JC, Nobuta H, Tsai HH, Heine VM, McKinsey GL, Meijer DH, Howard MA, Petryniak MA, Potter GB, Alberta JA, Baraban SC, Stiles CD, Rubenstein JL, Rowitch DH.

Neuron. 2014 Feb 5;81(3):574-87. doi: 10.1016/j.neuron.2013.11.024.

15.

New progenitors NESTIN(g) in the EGL.

Pak E, Segal RA, Stiles CD.

Nat Neurosci. 2013 Dec;16(12):1710-2. doi: 10.1038/nn.3580. No abstract available.

PMID:
24270268
16.

Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging.

Liu X, Ide JL, Norton I, Marchionni MA, Ebling MC, Wang LY, Davis E, Sauvageot CM, Kesari S, Kellersberger KA, Easterling ML, Santagata S, Stuart DD, Alberta J, Agar JN, Stiles CD, Agar NY.

Sci Rep. 2013 Oct 4;3:2859. doi: 10.1038/srep02859.

17.

Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.

Ramkissoon LA, Horowitz PM, Craig JM, Ramkissoon SH, Rich BE, Schumacher SE, McKenna A, Lawrence MS, Bergthold G, Brastianos PK, Tabak B, Ducar MD, Van Hummelen P, MacConaill LE, Pouissant-Young T, Cho YJ, Taha H, Mahmoud M, Bowers DC, Margraf L, Tabori U, Hawkins C, Packer RJ, Hill DA, Pomeroy SL, Eberhart CG, Dunn IF, Goumnerova L, Getz G, Chan JA, Santagata S, Hahn WC, Stiles CD, Ligon AH, Kieran MW, Beroukhim R, Ligon KL.

Proc Natl Acad Sci U S A. 2013 May 14;110(20):8188-93. doi: 10.1073/pnas.1300252110. Epub 2013 Apr 30.

18.

Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2.

Meijer DH, Kane MF, Mehta S, Liu H, Harrington E, Taylor CM, Stiles CD, Rowitch DH.

Nat Rev Neurosci. 2012 Dec;13(12):819-31. doi: 10.1038/nrn3386. Review.

19.

Asleep at the switch: MEK kinases control transit to gliogenesis in developing cortex.

Zhou J, Stiles CD.

Neuron. 2012 Sep 20;75(6):940-2. doi: 10.1016/j.neuron.2012.09.003.

20.

Prospective, high-throughput molecular profiling of human gliomas.

Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ.

J Neurooncol. 2012 Oct;110(1):89-98. doi: 10.1007/s11060-012-0938-9. Epub 2012 Jul 22.

21.

Identification of molecular compartments and genetic circuitry in the developing mammalian kidney.

Yu J, Valerius MT, Duah M, Staser K, Hansard JK, Guo JJ, McMahon J, Vaughan J, Faria D, Georgas K, Rumballe B, Ren Q, Krautzberger AM, Junker JP, Thiagarajan RD, Machanick P, Gray PA, van Oudenaarden A, Rowitch DH, Stiles CD, Ma Q, Grimmond SM, Bailey TL, Little MH, McMahon AP.

Development. 2012 May;139(10):1863-73. doi: 10.1242/dev.074005.

22.

Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.

Tian Y, Rich BE, Vena N, Craig JM, Macconaill LE, Rajaram V, Goldman S, Taha H, Mahmoud M, Ozek M, Sav A, Longtine JA, Lindeman NI, Garraway LA, Ligon AH, Stiles CD, Santagata S, Chan JA, Kieran MW, Ligon KL.

J Mol Diagn. 2011 Nov;13(6):669-77. doi: 10.1016/j.jmoldx.2011.07.002. Epub 2011 Aug 30.

23.

Report from the fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop.

Gutmann DH, Stiles CD, Lowe SW, Bollag GE, Furnari FB, Charest AL.

Neuro Oncol. 2011 Jul;13(7):692-9. doi: 10.1093/neuonc/nor080. Review.

24.

The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma.

Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, Alberta JA, Kane MF, Theisen M, Ligon KL, Rowitch DH, Stiles CD.

Cancer Cell. 2011 Mar 8;19(3):359-71. doi: 10.1016/j.ccr.2011.01.035.

25.

Phosphorylation state of Olig2 regulates proliferation of neural progenitors.

Sun Y, Meijer DH, Alberta JA, Mehta S, Kane MF, Tien AC, Fu H, Petryniak MA, Potter GB, Liu Z, Powers JF, Runquist IS, Rowitch DH, Stiles CD.

Neuron. 2011 Mar 10;69(5):906-17. doi: 10.1016/j.neuron.2011.02.005.

26.

Profiling critical cancer gene mutations in clinical tumor samples.

MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA.

PLoS One. 2009 Nov 18;4(11):e7887. doi: 10.1371/journal.pone.0007887. Erratum in: PLoS One. 2010;5(9). doi: 10.1371/annotation/3a0c8fee-57ef-43ed-b6c2-55b503e6db5e. PLoS One. 2010;5(9). doi: 10.1371/annotation/613c7509-e4c9-42ac-82fb-fc504400d9e0.

27.

A genome-wide screen for spatially restricted expression patterns identifies transcription factors that regulate glial development.

Fu H, Cai J, Clevers H, Fast E, Gray S, Greenberg R, Jain MK, Ma Q, Qiu M, Rowitch DH, Taylor CM, Stiles CD.

J Neurosci. 2009 Sep 9;29(36):11399-408. doi: 10.1523/JNEUROSCI.0160-09.2009.

28.

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD.

Neuro Oncol. 2009 Dec;11(6):853-60. doi: 10.1215/15228517-2009-010.

29.

Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.

Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW, Wen PY.

Neuro Oncol. 2009 Apr;11(2):109-21. doi: 10.1215/15228517-2008-060. Epub 2008 Aug 5.

30.

Glioma stem cells: a midterm exam.

Stiles CD, Rowitch DH.

Neuron. 2008 Jun 26;58(6):832-46. doi: 10.1016/j.neuron.2008.05.031. Review.

31.

Molecular pathogenesis of adult brain tumors and the role of stem cells.

Sauvageot CM, Kesari S, Stiles CD.

Neurol Clin. 2007 Nov;25(4):891-924, vii. Review.

PMID:
17964020
32.
33.

Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma.

Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, Depinho RA, Anderson DJ, Stiles CD, Rowitch DH.

Neuron. 2007 Feb 15;53(4):503-17.

34.

The bad seed: PDGF receptors link adult neural progenitors to glioma stem cells.

Kesari S, Stiles CD.

Neuron. 2006 Jul 20;51(2):151-3. Review.

35.

Development of NG2 neural progenitor cells requires Olig gene function.

Ligon KL, Kesari S, Kitada M, Sun T, Arnett HA, Alberta JA, Anderson DJ, Stiles CD, Rowitch DH.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7853-8. Epub 2006 May 8.

36.

Evidence for motoneuron lineage-specific regulation of Olig2 in the vertebrate neural tube.

Sun T, Hafler BP, Kaing S, Kitada M, Ligon KL, Widlund HR, Yuk DI, Stiles CD, Rowitch DH.

Dev Biol. 2006 Apr 1;292(1):152-64. Epub 2006 Feb 8.

37.

Targeted molecular therapy of malignant gliomas.

Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY.

Curr Oncol Rep. 2006 Jan;8(1):58-70.

PMID:
16464405
38.

Novel pheochromocytoma susceptibility loci identified by integrative genomics.

Dahia PL, Hao K, Rogus J, Colin C, Pujana MA, Ross K, Magoffin D, Aronin N, Cascon A, Hayashida CY, Li C, Toledo SP, Stiles CD; Familial Pheochromocytoma Consortium.

Cancer Res. 2005 Nov 1;65(21):9651-8.

39.

A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas.

Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS, Hodin R, Heitritter S, Moore F, Dluhy R, Sosa JA, Ocal IT, Benn DE, Marsh DJ, Robinson BG, Schneider K, Garber J, Arum SM, Korbonits M, Grossman A, Pigny P, Toledo SP, Nosé V, Li C, Stiles CD.

PLoS Genet. 2005 Jul;1(1):72-80. Epub 2005 Jul 25.

40.
41.

Targeted molecular therapy of malignant gliomas.

Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY.

Curr Neurol Neurosci Rep. 2005 May;5(3):186-97. Review.

PMID:
15865884
42.

Mouse brain organization revealed through direct genome-scale TF expression analysis.

Gray PA, Fu H, Luo P, Zhao Q, Yu J, Ferrari A, Tenzen T, Yuk DI, Tsung EF, Cai Z, Alberta JA, Cheng LP, Liu Y, Stenman JM, Valerius MT, Billings N, Kim HA, Greenberg ME, McMahon AP, Rowitch DH, Stiles CD, Ma Q.

Science. 2004 Dec 24;306(5705):2255-7.

43.

bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS.

Arnett HA, Fancy SP, Alberta JA, Zhao C, Plant SR, Kaing S, Raine CS, Rowitch DH, Franklin RJ, Stiles CD.

Science. 2004 Dec 17;306(5704):2111-5.

44.

Distinct temporal genetic signatures of neurogenic and gliogenic cues in cortical stem cell cultures.

Sauvageot C, Dahia PL, Lipan O, Park JK, Chang MS, Alberta JA, Stiles CD.

J Neurobiol. 2005 Jan;62(1):121-33.

45.

The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.

Ligon KL, Alberta JA, Kho AT, Weiss J, Kwaan MR, Nutt CL, Louis DN, Stiles CD, Rowitch DH.

J Neuropathol Exp Neurol. 2004 May;63(5):499-509.

PMID:
15198128
46.

Expression of the guanine nucleotide exchange factor, mr-gef, is regulated during the differentiation of specific subsets of telencephalic neurons.

Bithell A, Alberta J, Hornby F, Stiles CD, Williams BP.

Brain Res Dev Brain Res. 2003 Dec 19;146(1-2):107-18.

PMID:
14643017
48.
49.

Basic helix-loop-helix factors in cortical development.

Ross SE, Greenberg ME, Stiles CD.

Neuron. 2003 Jul 3;39(1):13-25. Review.

50.

High-resolution imaging demonstrates dynein-based vesicular transport of activated Trk receptors.

Bhattacharyya A, Watson FL, Pomeroy SL, Zhang YZ, Stiles CD, Segal RA.

J Neurobiol. 2002 Jun 15;51(4):302-12.

PMID:
12150505

Supplemental Content

Loading ...
Support Center